Nyxoah SA (NYXH)

10.08 -0.22 (-2.14%)
Close USD Disclaimer

Nyxoah SA Company Profile

Equity Type
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Contact Information
Mont-Saint-Guibert,1435 Belgium
32 1 022 23 55
Top Executives
Olivier Taelman 51 2019 CEO & Executive Director
Robert Taub 75 2009 Co-Founder & Chairman
Kevin L. Rakin 61 2016 Independent Non-Executive Director
Jurgen Hambrecht 76 2016 Independent Non-Executive Director
Rita Faye Johnson-Mills 63 2021 Independent Non-Executive Director
Pierre Gianello 65 2018 Non-Executive Director
Raymond W. Cohen 63 2022 Independent Non-Executive Director
Virginia M. Kirby 0 2022 Independent Non-Executive Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles